News
-
-
PRESS RELEASE
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 2 bonds in Oxurion, resulting in EUR 50,000 capital increase. Oxurion issues 55,555,555 new shares to align with Capital Commitment. Company's updated share information released -
-
-
-
-
PRESS RELEASE
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC, The Goldman Sachs Group, Inc and Goldman Sachs International
Oxurion NV receives transparency notifications from Atlas Special Opportunities II, LLC and The Goldman Sachs Group, Inc regarding changes in shareholding percentages -
-
-
PRESS RELEASE
Oxurion enters into exclusive negotiations to acquire the business and assets of Eclevar, a MedTech-focused CRO
Oxurion NV (Euronext Brussels: OXUR) to acquire French CRO Eclevar, expanding into MedTech CRO market. Transaction details and growth potential outlined. Exclusive negotiations aim to close by 31 December 2026